View Single Post
Old 22-09-15, 11:45   #1
Ladybbird
 
Ladybbird's Avatar
 
Join Date: Feb 2011
Posts: 47,628
Thanks: 27,642
Thanked 14,458 Times in 10,262 Posts
Ladybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond reputeLadybbird has a reputation beyond repute

Awards Showcase
Best Admin Best Admin Gold Medal Gold Medal 
Total Awards: 8

Breaking News World Anger >US Rich Man Stops POOR AIDS/Infection Sufferers Buying MEDs

Global Outrage and Disgust as GAY Ex-Hedge Funder, 32, Buys Rights to AIDS/Infection Drugs >>>

AND Raises Price 5500% From $13.50 to $750 PER PILL!!!

  • Martin Shkreli, 32, founder and chief executive of Turing Pharmaceuticals, purchased the rights to Daraprim in August for $55million
  • He raised the price of the drug form $13.50 per tablet to $750 per tablet

  • Shkreli has backed the decision, saying that his company 'needed to turn a profit on the drug'
  • Daraprim treats toxoplasmois, an opportunistic parasitic infection that can cause serious and life-threatening problems
  • Hillary Clinton weighed in on the issue, calling the price hike 'outrageous'
  • Shkreli called the editor of Fierce Biotech 'a moron' after he questioned the CEO's reasoning behind increasing the price of Daraprim

By Kelly Mclaughlin, Daily Mail UK, 22 September 2015






Martin Shkreli, 32, founder and chief executive of Turing Pharmaceuticals, purchased the rights to Daraprim which is used for treating life-threatening parasitic infections - for $55million. He raised the price of the drug form $13.50 per tablet to $750 per tablet.


Since the announcement, people across social media have criticized the price increase, but Shkreli has backed the decision, saying that his company 'need to turn a profit on the drug'.


'This isn't the greedy drug company trying to gouge patients, it is us trying to stay in business,' Shkreli said..


He added that many patients use the drug for less than a year and that the price is on par with drugs similar that are used to treat rare diseases.

END

Ladybbird is online now   Reply With Quote
The Following User Says Thank You to Ladybbird For This Useful Post:
BaZZa101 (25-09-15)